The timeline the trial actually showed
The first thing to check is the calendar. In STEP 1, the 68-week trial behind the Wegovy® label, the first 16 weeks were the dose escalation period, during which participants moved from 0.25 mg through 0.5 mg, 1 mg and 1.7 mg to the 2.4 mg maintenance dose, each step lasting four weeks. Weight change in those early weeks was modest by design, because the starting doses exist to let the body adjust, not to produce the result. The average change of 14.9 percent of body weight reported at 68 weeks, against 2.4 percent with placebo, accumulated over more than a year, and the curve flattened in the later months rather than falling steadily.
So a person four or six weeks in who has lost little is not off track by the trial’s own standard. A person six months in at a maintenance dose with no change at all is in a different situation, and that is the one worth a conversation with a provider. This study only applies to brand name product and personalized compounded versions cannot be referenced or used to compare in this study.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Reasons the labels and the trials point to
Still on a starting dose. The label describes 0.25 mg as an initiation dose that is not effective for chronic weight management on its own. Until the maintenance dose is reached, the medication is not doing what the trial measured. This applies only to the brand name product and personalized compounded versions should not be compared for results.
Missed or late doses. The label asks for one dose a week on a fixed day, and allows a missed dose to be taken within five days. Repeated gaps mean lower exposure than the schedule intends. Consult with your provider for guidance.
Intake has not changed. Every participant in STEP 1 followed a reduced calorie diet and increased activity. The medication reduces appetite for most people; it does not count calories. Liquid calories, grazing and large portions at the one meal a person still feels hungry for are the usual pattern a provider hears about.
Eating too little. The opposite problem is just as common. Very low intake leads to fatigue, loss of lean mass and, for some people, a stall. The site’s guide on eating too little on a GLP-1 medication covers this in detail.
Other medications and conditions. Some medications are associated with weight gain, and conditions such as hypothyroidism, polycystic ovary syndrome and poor sleep can slow progress. These belong in the provider conversation, not in self-diagnosis.
A plateau after real loss. Weight loss in the trial slowed and levelled in the final months. A plateau after months of progress is the expected shape of the curve, not a failure of the medication.
Individual variation. The label reports that in STEP 1, 83.5 percent of participants on semaglutide lost at least 5 percent of body weight, which means a meaningful minority did not reach even that threshold. Response varies and no outcome is guaranteed for anyone. This study information applies to the brand name product and the outcome cannot be compared for a personalized compounded version.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What a provider can actually do
A licensed provider looks at the dose and how long the patient has been on it, the dosing record, the eating pattern, sleep, other medications and any symptoms, and then decides whether to hold the dose, step it up within the label’s schedule, address something else first, or consider a different medication. Dose decisions are theirs. At Bodi Envi, dose changes are included in every plan price, so a change the provider recommends does not change the monthly cost, and the patient portal is where to raise it between visits.
This is general information and not medical advice. The label and trial describe Wegovy®, the branded product. Personalized Compounded semaglutide, which Bodi Envi’s programs may include, is not FDA-approved, was not studied and is not equivalent to Wegovy®. Comparisons cannot be made with an FDA approved product versus the personalized compounded version.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.